Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Jeroen V KoomenHiddo J Lambers HeerspinkIlse C SchrieksGregory G SchwartzA Michael LincoffStephen J NichollsAnders SvenssonHans WedelArlette WeichertDiederick E GrobbeeJasper StevensPublished in: Diabetes, obesity & metabolism (2019)
Concomitant use of clopidogrel was identified as a covariate that explained interindividual variability in exposure to aleglitazar. Patients using clopidogrel showed an additional lowering of HbA1c, at the expense of an additional decrease in haemoglobin, and an increase in serum creatinine and adiponectin. Clopidogrel is a moderate inhibitor of CYP2C8. Because aleglitazar is metabolized by CYP2C8, a pharmacokinetic interaction could explain differences in exposure and response to aleglitazar.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- metabolic syndrome
- prognostic factors
- peritoneal dialysis
- type diabetes
- randomized controlled trial
- skeletal muscle
- uric acid
- patient reported outcomes
- high intensity
- phase ii
- weight loss
- double blind